Stocktoria
SAB Biotherapeutics, Inc. SABS
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2021-01-12
Chart by TradingView
3/9
Piotroski F — financial health
6.9
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | $0 | $1.3M | $2.2M | $23.9M | $60.9M |
| Operating income | -$49.0M | -$42.9M | -$38.1M | -$28.9M | -$13.4M |
| Net income | $13.3M | -$34.1M | -$42.2M | -$18.7M | -$17.1M |
| Operating cash flow | -$44.8M | -$34.3M | -$25.1M | -$23.5M | $2.0M |
| Free cash flow | -$45.7M | -$34.6M | -$25.3M | -$25.6M | -$9.0M |
| Total assets | $172.8M | $44.2M | $83.9M | $50.9M | $81.1M |
| Total liabilities | $21.3M | $18.2M | $26.6M | $19.8M | $42.6M |
| Shareholders' equity | $151.5M | $26.0M | $57.3M | $31.1M | $38.5M |
| Ratios | |||||
| Operating margin | — | -3244.9% | -1700.6% | -121.0% | -22.0% |
| Net margin | — | -2579.0% | -1884.5% | -78.4% | -28.2% |
| FCF margin | — | -2618.6% | -1130.7% | -107.2% | -14.7% |
| Return on assets | 7.7% | -77.2% | -50.3% | -36.8% | -21.1% |
| Return on equity | 8.8% | -131.3% | -73.6% | -60.3% | -44.5% |
| Current ratio | 9.46 | 2.98 | 5.45 | 1.47 | 1.90 |
| Revenue growth | -100.0% | -40.9% | -90.6% | -60.7% | 10.2% |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 6.9 (safe)
- Working capital / assets 0.523
- Retained earnings / assets -0.642
- EBIT / assets -0.283
- Equity / liabilities 7.107
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001833214 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.